ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

This study compares two treatment strategies for people with advanced liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed: immune checkpoint blockers combined with anti-VEGF drugs (which block blood vessel growth in tumors), either with or without additional tumor-targeting procedures like TACE (a form of chemotherapy delivered directly to the liver). **You may be eligible if...** - You are 18 or older with confirmed hepatocellular carcinoma - Your cancer is at BCLC Stage B or C (intermediate to advanced) - You have at least one measurable tumor - Your liver function is relatively preserved (Child-Pugh A or B) - Your ECOG performance score is 0 or 1 - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - You are a candidate for curative surgery or liver transplant - You are pregnant or breastfeeding - You have an active autoimmune disease - You have received local liver treatments (TACE, ablation, etc.) within the past 4 weeks - You had another cancer within the past 5 years Talk to your doctor to see if this trial is right for you.